| |
|
|
|
Xtalks, online
2022 -11-03
The adoption of decentralized and agile clinical trials has increased exponentially over the past few years. As adoption accelerates, so do the possibilities that a decentralized clinical trial (DCT) enables. Oncology trials have especially benefited with DCT practices.
In this webinar, Dr. Shaalan Beg, MD, MS, Vice President, Oncology, at Science 37 will host a conversation with a group of industry leaders, discussing what current clinical research looks like with oncology trials. The panel will share the value that agile approaches deliver to patients, sponsors, sites and CROs — giving examples of how decentralized elements are incorporated in oncology trials today, and how the landscape will change in the years to come.
Register to learn what oncology trials look like now with the adoption of decentralized practices.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
James Chase (Moderator), Senior Director, Thought Leadership, Science 37 Dr. Shaalan Beg, MD, MS, Vice President, Oncology, Science 37 Dr. Aasma Shaukat, Professor of Gastroenterology and Medicine, NYU Grossman School of Medicine Andrew J. Mckenzie, PhD, Vice President, Personalized Medicine, Sarah Cannon
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2022 -11-03
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|